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necessity and concerns may be useful for crafting actionable mes-
saging to overcome barriers to medication adherence.
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ASSOCIATION OF ANTIHYPERTENSIVE MEDICATION CLASS
WITH BLOOD PRESSURE CONTROL AND PERSISTENCE ON
MONOTHERAPY
Smith KL, Malone DC, Bhandary D
University of Arizona,Tucson, AZ, USA
OBJECTIVES: Determine the association between antihyperten-
sive medication class and blood pressure (BP) control and deter-
mine persistence of subjects on monotherapy for hypertension in
veterans. METHODS: Blood pressure (BP) measurements and
pharmacy records were obtained from Southern Arizona Veter-
ans Affairs Healthcare System. Variables of interest included
demographics, BP measurements, and pharmacy dispensings.
Medications classiﬁed by VA class codes included ten distinct
subclasses. Mean systolic BP (SBP) and diastolic BPs (DBP) were
categorized according to JNC-7 classiﬁcations. Association of 
BP control using mean SBP and antihypertensive class was deter-
mined. Medication persistence was calculated. Cox proportional
hazards analysis was performed to examine the hazard ratio
(HR) of discontinuation of medication class. RESULTS: A total
of 16,195 veterans obtained 49,254 antihypertensive medication
dispensings from August 12, 2002 to February 2, 2004. Of these,
4787 received monotherapy. For persons on monotherapy, mean
(SD) age was 64.9 +12.8 years; 93.4% were male. A total of 346
had normal SBP, but 4441 subjects had high SBP. Mean SBP
control was signiﬁcantly different between antihypertensive
classes(X2 = 7.9e + 3, p < 0.001). Use of beta-blockers and ACE-
inhibitors were more likely to be associated with subjects who
had controlled blood pressure, 47.1% and 23.1% respectively.
Among subjects with high SBP, beta-blockers and ACE-inhibitors
were used in 34.5% and 30.9% of subjects. The likelihood of
discontinuing therapy was statistically signiﬁcantly lower among
subjects receiving angiotensin receptor blockers (ARB), (HR
0.31, 95% CI 0.1–0.9). CONCLUSIONS: Among veterans
taking antihypertensive monotherapy, subjects on beta-blockers
were more likely to have controlled BP compared to other anti-
hypertensive medication classes. This could be due to high pre-
scribing rates, not necessarily success or failure as monotherapy.
Side effects/preference may lead to different persistence rates
between classes, but persons on ARBs were less likely to dis-
continue therapy. These results should be viewed cautiously since
the analysis may have been inﬂuenced by unmeasured patient
characteristics and formulary considerations.
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OBJECTIVES: In clinical trials the quality of life (QL) level was
a determinant of patient adherence to treatment, while such rela-
tionships during routine hypertension management are less clear.
The study aim was to evaluate predictors of self-reported adher-
ence to drug therapy and its relation to QL level in patients
referred to a specialized hypertension facility. METHODS: In 
a random sample of 238 hypertensives (116 males; aged 49
(43–57) years (median, quartile range)) we performed standard-
ized interview and QL assessment with validated questionnaires:
the General Well-Being Adjustment Scale and the Giessen
Somatic Complaints Questionnaire. Total Well-Being Index
(TWBI) and Total Complaints Intensity (TCI) were calculated in
groups of patients (GrA) treated on regular basis (62), (GrB)
those taking drugs irregularly (116), and (GrC) ones with known
but untreated hypertension (60). The same information was suc-
cessfully obtained by postal survey for 40 out of 104 patients
resided in city area after 61 months (range 32–73) of follow-up.
RESULTS: In GrC TWBI were the highest (88 (75–99.5) vs. 80
(69–88) in GrA, 80 (71–91.5) in GrB; p-value for Kruskal-Wallis
ANOVA 0.032), while TCI was the lowest (20.5 (10.5–34) vs.
33.5 (18–48) in GrA, 29 (16–38) in GrB; p = 0.003). Other com-
pliance predictors were age (42.5 (29.5–50) years in untreated
patients vs. 52 (46–59) in GrA, 50 (44–57) in GrB; p < 0.0001)
and gender (42% of men vs. 9% of women fell into GrC; p <
0.0001). During follow-up TWBI and TCI did not change sig-
niﬁcantly in any group, while TCI after follow-up was even
lower in patients twice reported absence of regular treatment (15
(12–29) in combined GrB+GrC vs. 36 (25–43) in GrA; p =
0.017). CONCLUSIONS: Long-term high QL level seems to be
related to low adherence to antihypertensive therapy. QL proﬁle
might be promising additional factor for risk stratiﬁcation during
routine hypertension management.
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OBJECTIVES: Hypertension and dyslipidemia elevate risk of
cardiovascular diseases in diabetic patients. The risk, however,
can be reduced considerably by drug therapy. Therefore, adher-
ence with prescribed drug therapy is especially important. The
study described adherence patterns of major drug classes of oral
antidiabetic (AD), antihypertensive (AH), and lipid-lowering
(LL) therapy in veterans with type 2 diabetes. METHODS: The
study used VA pharmacy prescription data from 1998 to 2004.
Patients were included if they initiated at least one of AD/AH/LL
in 2000. Concomitant therapy was deﬁned as initiating at least
two of AD/AH/LL within 90 days. Compliance was measured in
six-month intervals following initiation of therapy. Patients were
considered compliant if ﬁlled prescriptions were sufﬁcient for
covering >= 80% of days. Persistence was measured as the
number of days of continuous therapy, with 60 days between 2
prescriptions as the grace period. RESULTS: A total of 65,806,
31,910, and 48,445 patients were examined for adherence to
AD, AH, and LL, respectively. Angiotensin receptor blockers
(ARBs) had the longest mean persistence (AH, 787.7 days), fol-
lowed by â-blockers (AH, 764.7 days), sulfonylureas (AD, 734.7
days), ACE inhibitors (AH, 726.3 days), calcium channel block-
ers (AH, 708.1 days), metformin (AD, 700.0 days), á-blockers
(AH, 698.5 days), thiazolidinediones (AD, 674.0 days), statins
(LL, 663.6 days), diuretics (AH, 660.3 days), and ﬁbrates (LL,
557.8 days). Percentage of patients adherent with therapy
dropped sharply within ﬁrst 6 months, ranged from 49.4%
(ﬁbrates) to 66.8% (ARBs), and declined slowly afterwards.
ANOVA analyses indicated that concomitant therapy and use 
of Consolidated Mail Outpatient Pharmacy (CMOP) were 
associated with better compliance and longer persistence in 
most drug classes (P < 0.05), except ARBs (nonsigniﬁcant).
CONCLUSIONS: Adherence with AD, AH, and LL therapy in
veterans declines substantially over time. Adherence may be
improved by initiating AD, AH, and LL concomitantly and use
of CMOP.
